Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cash from Investing Activities (2022 - 2025)

Historic Cash from Investing Activities for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$27000.0.

  • Phathom Pharmaceuticals' Cash from Investing Activities rose 3863.64% to -$27000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$147000.0, marking a year-over-year increase of 7570.25%. This contributed to the annual value of -$135000.0 for FY2024, which is 9173.81% up from last year.
  • According to the latest figures from Q3 2025, Phathom Pharmaceuticals' Cash from Investing Activities is -$27000.0, which was up 3863.64% from -$97000.0 recorded in Q2 2025.
  • Over the past 5 years, Phathom Pharmaceuticals' Cash from Investing Activities peaked at -$5000.0 during Q4 2024, and registered a low of -$939000.0 during Q3 2023.
  • Moreover, its 4-year median value for Cash from Investing Activities was -$67000.0 (2022), whereas its average is -$196800.0.
  • Over the last 5 years, Phathom Pharmaceuticals' Cash from Investing Activities had its largest YoY gain of 9894.74% in 2024, and its largest YoY loss of 66666.67% in 2024.
  • Phathom Pharmaceuticals' Cash from Investing Activities (Quarter) stood at -$412000.0 in 2022, then fell by 15.29% to -$475000.0 in 2023, then skyrocketed by 98.95% to -$5000.0 in 2024, then plummeted by 440.0% to -$27000.0 in 2025.
  • Its last three reported values are -$27000.0 in Q3 2025, -$97000.0 for Q2 2025, and -$18000.0 during Q1 2025.